Agios Pharmaceuticals Inc (AGIO)

Nov 23, 2025

Should You Follow Insider Buying Trends for Multipurpose Trading and Agencies LimitedStraddle and Strangle Trades & Trusted Financial Advisors at No Cost - earlytimes.in

Nov 23, 2025

Nov 23, 2025

9 Oversold Biotech Stocks to Invest In - Insider Monkey

Nov 23, 2025

Nov 23, 2025

The week in pharma: action, reaction and insight – week to November 21 - The Pharma Letter

Nov 23, 2025

Nov 22, 2025

Agios rebounds as Leerink upgrades to Outperform on selloff - MSN

Nov 22, 2025

Nov 21, 2025

Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN

Nov 21, 2025

Nov 21, 2025

AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutral Rating | AGIO Stock News - GuruFocus

Nov 21, 2025

Nov 20, 2025

Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data - Investing.com Canada

Nov 20, 2025

Nov 20, 2025

Leerink Partners upgrades Agios Pharma stock on thalassemia potential By Investing.com - Investing.com Canada

Nov 20, 2025

Nov 20, 2025

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Yahoo Finance

Nov 20, 2025

Nov 20, 2025

How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Yahoo Finance

Nov 20, 2025

Nov 20, 2025

Agios slumps on mixed Phase III trial of mitapivat in sickle cell disease - The Pharma Letter

Nov 20, 2025

Nov 20, 2025

Agios stock rebounds as Leerink upgrades (AGIO:NASDAQ) - Seeking Alpha

Nov 20, 2025

Nov 20, 2025

Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesStock Surge & Safe Capital Allocation Plans - newser.com

Nov 20, 2025

Nov 20, 2025

Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug - Stocktwits

Nov 20, 2025

Nov 20, 2025

Agios Pharma stock plunges on mixed Pyrukynd sickle cell trial results - Investing.com India

Nov 20, 2025

Nov 20, 2025

AGIO: Leerink Partners Upgrades Rating, Lowers Price Target | AG - GuruFocus

Nov 20, 2025

Nov 20, 2025

AGIO: Goldman Sachs Lowers Price Target, Maintains Neutral Ratin - GuruFocus

Nov 20, 2025

Nov 20, 2025

Leerink Partners upgrades Agios Pharma stock on thalassemia potential - Investing.com India

Nov 20, 2025

Nov 20, 2025

Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs - TipRanks

Nov 20, 2025

Nov 20, 2025

Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Tria - GuruFocus

Nov 20, 2025

Nov 20, 2025

Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Nov 20, 2025

Nov 20, 2025

RBC Downgrades Agios Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $28 From $57 - MarketScreener

Nov 20, 2025

Nov 20, 2025

Leerink Partners Upgrades Agios Pharmaceuticals to Outperform From Market Perform, PT is $34 - MarketScreener

Nov 20, 2025

Nov 20, 2025

AGIO: HC Wainwright Lowers Price Target But Maintains Buy Rating - GuruFocus

Nov 20, 2025

Nov 20, 2025

Published on: 2025-11-20 04:28:25 - newser.com

Nov 20, 2025

Nov 20, 2025

Published on: 2025-11-20 00:18:11 - newser.com

Nov 20, 2025

Nov 20, 2025

How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com

Nov 20, 2025

Nov 19, 2025

Published on: 2025-11-19 21:36:35 - newser.com

Nov 19, 2025

Nov 19, 2025

Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts - newser.com

Nov 19, 2025

Nov 19, 2025

How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsOil Prices & Fast Entry and Exit Trade Plans - newser.com

Nov 19, 2025

Nov 19, 2025

Published on: 2025-11-19 18:19:52 - newser.com

Nov 19, 2025

Nov 19, 2025

Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results By Investing.com - Investing.com South Africa

Nov 19, 2025

Nov 19, 2025

Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results - Citeline News & Insights

Nov 19, 2025

Nov 19, 2025

Will Agios Pharmaceuticals Inc. stock see PE expansionProduct Launch & High Return Trade Opportunity Guides - newser.com

Nov 19, 2025

Nov 19, 2025

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results - Markets Financial Content

Nov 19, 2025

Nov 19, 2025

Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech

Nov 19, 2025

Nov 19, 2025

This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily

Nov 19, 2025

Nov 19, 2025

Agios reports mixed results in sickle cell disease trial of mitapivat - Investing.com Nigeria

Nov 19, 2025

Nov 19, 2025

Agios Pharma: Study Fail May Affect Mitapivat TDT ApprovalExpect More Volatility (AGIO) - Seeking Alpha

Nov 19, 2025

Nov 19, 2025

Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results - Investing.com UK

Nov 19, 2025

Nov 19, 2025

Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat - Nasdaq

Nov 19, 2025

Nov 19, 2025

Why Shares in Agios Pharmaceuticals Got Crushed Today - AOL.com

Nov 19, 2025

Nov 19, 2025

Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data - GuruFocus

Nov 19, 2025

Nov 19, 2025

Agios Pharma stock rating downgraded by RBC Capital after mixed trial data - Investing.com

Nov 19, 2025

Nov 19, 2025

Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool

Nov 19, 2025

Nov 19, 2025

RBC downgrades Agios to Sector Perform after mitapivat ‘falls short’ - TipRanks

Nov 19, 2025

Nov 19, 2025

Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Resul - GuruFocus

Nov 19, 2025

Nov 19, 2025

Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results - Benzinga

Nov 19, 2025

Nov 19, 2025

Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price - GuruFocus

Nov 19, 2025

Nov 19, 2025

Agios shares fall on mixed sickle cell results for blood disease drug - BioPharma Dive

Nov 19, 2025

Nov 19, 2025

Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga

Nov 19, 2025